These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 30020783)

  • 21. Immune Checkpoint Inhibitors for Cancer Therapy: Clinical Efficacy and Safety.
    Azoury SC; Straughan DM; Shukla V
    Curr Cancer Drug Targets; 2015; 15(6):452-62. PubMed ID: 26282545
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Dendritic cell and cancer immune checkpoint].
    Kubo T; Hirohashi Y; Torigoe T
    Nihon Rinsho Meneki Gakkai Kaishi; 2016; 39(5):468-472. PubMed ID: 27795504
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Toxicity of immune checkpoints inhibitors].
    Delaunay M; Caron P; Sibaud V; Godillot C; Collot S; Milia J; Prévot G; Mazières J
    Rev Mal Respir; 2018 Dec; 35(10):1028-1038. PubMed ID: 30213624
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Regulatory T cells: a potential target in cancer immunotherapy.
    Shitara K; Nishikawa H
    Ann N Y Acad Sci; 2018 Apr; 1417(1):104-115. PubMed ID: 29566262
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Rationale for anti-GITR cancer immunotherapy.
    Knee DA; Hewes B; Brogdon JL
    Eur J Cancer; 2016 Nov; 67():1-10. PubMed ID: 27591414
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immune Checkpoint Blockade in Breast Cancer Therapy.
    Bu X; Yao Y; Li X
    Adv Exp Med Biol; 2017; 1026():383-402. PubMed ID: 29282694
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunotherapy for the treatment of breast cancer: checkpoint blockade, cancer vaccines, and future directions in combination immunotherapy.
    McArthur HL; Page DB
    Clin Adv Hematol Oncol; 2016 Nov; 14(11):922-933. PubMed ID: 27930644
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Targeting T Cell Co-receptors for Cancer Therapy.
    Callahan MK; Postow MA; Wolchok JD
    Immunity; 2016 May; 44(5):1069-78. PubMed ID: 27192570
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immune checkpoint blockade therapy for cancer: An overview of FDA-approved immune checkpoint inhibitors.
    Hargadon KM; Johnson CE; Williams CJ
    Int Immunopharmacol; 2018 Sep; 62():29-39. PubMed ID: 29990692
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immune Checkpoint-Mediated Interactions Between Cancer and Immune Cells in Prostate Adenocarcinoma and Melanoma.
    Elia AR; Caputo S; Bellone M
    Front Immunol; 2018; 9():1786. PubMed ID: 30108594
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety of combining radiotherapy with immune-checkpoint inhibition.
    Hwang WL; Pike LRG; Royce TJ; Mahal BA; Loeffler JS
    Nat Rev Clin Oncol; 2018 Aug; 15(8):477-494. PubMed ID: 29872177
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Modulation of tumor immunity: a patent evaluation of WO2015026684A1.
    Nocentini G; Cari L; Ronchetti S; Riccardi C
    Expert Opin Ther Pat; 2016; 26(3):417-25. PubMed ID: 26560753
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Rational design of anti-GITR-based combination immunotherapy.
    Zappasodi R; Sirard C; Li Y; Budhu S; Abu-Akeel M; Liu C; Yang X; Zhong H; Newman W; Qi J; Wong P; Schaer D; Koon H; Velcheti V; Hellmann MD; Postow MA; Callahan MK; Wolchok JD; Merghoub T
    Nat Med; 2019 May; 25(5):759-766. PubMed ID: 31036879
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Development of Cancer Immunotherapy Targeting the PD-1 Pathway.
    Kamimura N; Wolf AM; Iwai Y
    J Nippon Med Sch; 2019; 86(1):10-14. PubMed ID: 30918149
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cutaneous Adverse Events of Immune Checkpoint Inhibitors: A Summarized Overview.
    Plachouri KM; Vryzaki E; Georgiou S
    Curr Drug Saf; 2019; 14(1):14-20. PubMed ID: 30058498
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Cancer immunotherapy by immuno-checkpoint blockade].
    Kawakami Y
    Rinsho Ketsueki; 2015 Oct; 56(10):2186-94. PubMed ID: 26458459
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mechanistic and pharmacologic insights on immune checkpoint inhibitors.
    Sweis RF; Luke JJ
    Pharmacol Res; 2017 Jun; 120():1-9. PubMed ID: 28323141
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Interventional therapy combined with immune checkpoint inhibitors: Emerging opportunities for cancer treatment in the era of immunotherapy.
    Chang X; Lu X; Guo J; Teng GJ
    Cancer Treat Rev; 2019 Mar; 74():49-60. PubMed ID: 30831375
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A Novel Murine GITR Ligand Fusion Protein Induces Antitumor Activity as a Monotherapy That Is Further Enhanced in Combination with an OX40 Agonist.
    Leyland R; Watkins A; Mulgrew KA; Holoweckyj N; Bamber L; Tigue NJ; Offer E; Andrews J; Yan L; Mullins S; Oberst MD; Coates Ulrichsen J; Leinster DA; McGlinchey K; Young L; Morrow M; Hammond SA; Mallinder P; Herath A; Leow CC; Wilkinson RW; Stewart R
    Clin Cancer Res; 2017 Jul; 23(13):3416-3427. PubMed ID: 28069723
    [No Abstract]   [Full Text] [Related]  

  • 40. Structural basis of checkpoint blockade by monoclonal antibodies in cancer immunotherapy.
    Lee JY; Lee HT; Shin W; Chae J; Choi J; Kim SH; Lim H; Won Heo T; Park KY; Lee YJ; Ryu SE; Son JY; Lee JU; Heo YS
    Nat Commun; 2016 Oct; 7():13354. PubMed ID: 27796306
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.